Table 1 532 IESS patients’demographics and inter-group analysis of response and nonresponse
Characteristic | Overall, N = 5321 | Nonresponse, N = 3721 | Response, N = 1601 | p-value |
|---|---|---|---|---|
Age_of_seizure_oneset | Â | Â | Â | 0.0182 |
Median (IQR) | 5.0 (3.0, 7.1) | 5.0 (3.0, 7.0) | 5.5 (4.0, 7.5) | Â |
Age_of_spasm_oneset | Â | Â | Â | 0.2032 |
Median (IQR) | 5.5 (4.0, 8.0) | 5.0 (3.5, 8.0) | 6.0 (4.5, 7.5) | Â |
Treatment_age | Â | Â | Â | 0.6102 |
Median (IQR) | 7.5 (5.5, 11.0) | 7.5 (5.5, 12.0) | 7.5 (6.0, 10.0) | Â |
Lead_time | Â | Â | Â | 0.5092 |
Median (IQR) | 1.50 (0.50, 3.00) | 1.50 (0.50, 3.50) | 1.50 (1.00, 3.00) | Â |
Gender | Â | Â | Â | 0.3363 |
Male | 306 (57.5%) | 219 (58.9%) | 87 (54.4%) | Â |
Female | 226 (42.5%) | 153 (41.1%) | 73 (45.6%) | Â |
First_seizure_type | Â | Â | Â | 0.1063 |
Non spasm | 113 (21.2%) | 86 (23.1%) | 27 (16.9%) | Â |
Spasm | 419 (78.8%) | 286 (76.9%) | 133 (83.1%) | Â |
Onset_early | Â | Â | Â | 0.0013 |
≤ 3 months | 106 (19.9%) | 88 (23.7%) | 18 (11.3%) |  |
˃ 3months | 426 (80.1%) | 284 (76.3%) | 142 (88.8%) |  |
Spasm_late_onset | Â | Â | Â | 0.2053 |
≤ 12 months | 475 (89.3%) | 328 (88.2%) | 147 (91.9%) |  |
>12 months and ≤ 24months | 57 (10.7%) | 44 (11.8%) | 13 (8.1%) |  |
Other_type_during_spasm | Â | Â | Â | 0.4133 |
With other seizure type | 108 (20.3%) | 79 (21.2%) | 29 (18.1%) | Â |
Without other seizure type | 424 (79.7%) | 293 (78.8%) | 131 (81.9%) | Â |
Hypsarrhythmia | Â | Â | Â | 0.5733 |
No | 190 (35.7%) | 130 (34.9%) | 60 (37.5%) | Â |
Yes | 342 (64.3%) | 242 (65.1%) | 100 (62.5%) | Â |
Development_delay_prior_to_spasms_onset | Â | Â | Â | 0.5593 |
Yes | 237 (45.0%) | 169 (45.8%) | 68 (43.0%) | Â |
No | 290 (55.0%) | 200 (54.2%) | 90 (57.0%) | Â |
Treatment |  |  |  | < 0.0013 |
ACTH | 420 (78.9%) | 282 (75.8%) | 138 (86.3%) | Â |
Oral costeroids | 51 (9.6%) | 48 (12.9%) | 3 (1.9%) | Â |
VGB | 61 (11.5%) | 42 (11.3%) | 19 (11.9%) | Â |
MRI | Â | Â | Â | 0.1313 |
Abnormal | 354 (66.5%) | 240 (64.5%) | 114 (71.3%) | Â |
Normal | 178 (33.5%) | 132 (35.5%) | 46 (28.8%) | Â |
MRI_type | Â | Â | Â | 0.5673 |
Acquired | 115 (21.6%) | 74 (19.9%) | 41 (25.6%) | Â |
Congenital | 239(44.9%) | 194 (44.6%) | 81 (45.6%) | Â |
Normal | 178 (33.5%) | 103 (35.5%) | 46 (28.8%) | Â |
MRI_subtype | Â | Â | Â | 0.1473 |
Perinatal acquired brain injury | 84 (15.8%) | 51 (13.7%) | 33 (20.6%) | Â |
Postnatal acquired brain injury | 31 (5.8%) | 23 (6.2%) | 8 (5.0%) | Â |
Developmental tumor | 22 (4.1%) | 12 (3.2%) | 10 (6.3%) | Â |
Normal | 178 (33.5%) | 132 (35.5%) | 46 (28.8%) | Â |
MCD | 93 (17.5%) | 62 (16.7%) | 31 (19.4%) | Â |
Volume Loss | 32 (6.0%) | 25 (6.7%) | 7 (4.4%) | Â |
DBD | 92 (17.3%) | 67 (18.0%) | 25 (15.6%) | Â |
IESS Classification | Â | Â | Â | 0.0783 |
Acquired structural abnormalities | 115 (21.6%) | 74 (19.9%) | 41 (25.6%) | Â |
Congenital structural abnormalities with positive genetic finding | 101 (19.0%) | 77 (20.7%) | 24 (15.0%) | Â |
Normal structure with positive genetic finding | 51 (9.6%) | 41 (11.0%) | 10 (6.3%) | Â |
Congenital structural abnormalities without positive genetic finding | 138 (25.9%) | 89 (23.9%) | 49 (30.6%) | Â |
Unknown | 127 (23.9%) | 91 (24.5%) | 36 (22.5%) | Â |